Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 1995 Jul;2(4):365-71.
doi: 10.1007/BF02307071.

Potential uses of interferon alpha 2 as adjuvant therapy in cancer

S S Agarwala  1 , J M Kirkwood
Affiliations
Review

Potential uses of interferon alpha 2 as adjuvant therapy in cancer

S S Agarwala et al. Ann Surg Oncol. 1995 Jul.

Abstract

Background: The purpose of this study was to provide an overview of the potential uses of adjuvant interferon (IFN) therapy for resected solid tumors at high risk for postsurgical relapse.

Methods: A MEDLINE search (1970-1994) of the English-language literature for original articles, reviews, and abstracts addressing IFN use in the adjuvant setting together with the authors' collective experience formed the basis for this review.

Results: The use of adjuvant IFN-alpha has been studied most extensively in conjunction with the treatment of melanoma. Fewer data are available on IFN-alpha use for the treatment of other solid tumors. In melanoma, there is evidence from Intergroup trials (Eastern Cooperative Oncology Group and World Health Organization) that IFN-alpha 2a given for 1-3 years prolongs the interval to relapse and may have a survival benefit. Trials of adjuvant IFN, with and without chemotherapy, are ongoing in the treatment of renal cell carcinoma and colorectal adenocarcinoma. Its value in the treatment of osteosarcoma and high-grade astrocytoma is unknown.

Conclusions: The use of IFN in the adjuvant setting is an exciting area of medical and surgical oncology and has the potential to prolong the time to relapse and to increase survival of patients with melanoma. Its role in the adjuvant therapy of other solid tumors remains to be defined.

PubMed Disclaimer

References

    1. J Invest Dermatol. 1990 Dec;95(6 Suppl):193S-197S - PubMed
    1. Science. 1985 Nov 15;230(4727):777-83 - PubMed
    1. Proc Natl Acad Sci U S A. 1982 May;79(10):3082-6 - PubMed
    1. J Biol Chem. 1994 Jul 29;269(30):19523-9 - PubMed
    1. Cancer. 1989 May 15;63(10):1990-3 - PubMed

MeSH terms

LinkOut - more resources